drugset

drugset / Trial / NCT06674135

Evaluating the Impact of Introducing Basaglar, a Long-acting Analog Insulin, on Clinical and Quality of Life Outcomes in Youth with Diabetes in Bangladesh

NCT06674135 ↗

Phase 4 Completed 202 enrolled Life for a Child Program, Diabetes Australia BADAS-Centre for Health Research and Implementation · collab Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders · collab Diabetic Association of Bangladesh (BADAS) · collab

NaSingle-groupOpen-labelTreatment

Summary

This study aimed to determine the effect of introducing Basaglar and insulin pen injection devices on clinical and quality of life (QOL) parameters in children and young adults with type 1 diabetes in Bangladesh

Timeline

Start: 2022-06-01
Primary completion: 2023-08-31
Completion: 2023-08-31

Publications

Background Skinner TC, Hoey H, McGee HM, Skovlund SE; Hvidore Study Group on Childhood Diabetes. A short form of the Diabetes Quality of Life for Youth questionnaire: exploratory and confirmatory analysis in a sample of 2,077 young people with type 1 diabetes mellitus. Diabetologia. 2006 Apr;49(4):621-8. doi: 10.1007/s00125-005-0124-0. Epub 2006 Jan 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	insulin glargine	Protein / enzyme biologic	—	—

Indications